Esaxerenone clinical trials
Also written CS-3150.
How each study uses esaxerenone is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
11 studies that test it; most in 2016 (7)
| Year | Studies |
|---|---|
| 2015 | 4 |
| 2016 | 7 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 11 · Other 0
Studies
Open first, then newest update. How each study uses esaxerenone is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 11
- Long-term Study of CS-3150 as Monotherapy or in Combination With Other Antihypertensive Drug in Japanese Patients With Essential HypertensionCompletedPhase 3Daiichi Sankyo Co., Ltd.NCT02722265Written as CS-3150How we know
- A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Hypertensive SubjectsCompletedPhase 2Daiichi SankyoNCT02345044Written as CS-3150How we know
- A Phase 2 Exploratory Study of CS-3150 in Japanese Hypertensive Patients With Moderate Renal ImpairmentCompletedPhase 2Daiichi SankyoNCT02448628Written as CS-3150How we know
- The Effect of CS-3150 Exposure on Corrected QT (QTc) Interval Duration in Healthy VolunteersCompletedPhase 1Daiichi SankyoNCT04019652Written as CS-3150How we know
- Study of CS-3150 in Hypertensive Patients With Type 2 Diabetes and AlbuminuriaCompletedPhase 3Daiichi Sankyo Co., Ltd.NCT02807974Written as CS-3150How we know
- Study of CS-3150 in Patients With Primary AldosteronismCompletedNot applicableDaiichi Sankyo Co., Ltd.NCT02885662Written as CS-3150How we know
- Study of CS-3150 in Patients With Essential HypertensionCompletedPhase 3Daiichi Sankyo Co., Ltd.NCT02890173Written as CS-3150How we know
- A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Type 2 Diabetic Subjects With MicroalbuminuriaCompletedPhase 2Daiichi SankyoNCT02345057Written as CS-3150How we know
- Study of CS-3150 in Patients With Severe HypertensionCompletedPhase 3Daiichi Sankyo Co., Ltd.NCT02808026Written as CS-3150How we know
- Study of CS-3150 Compared to Olmesartan in Patients With Essential HypertensionCompletedNot applicableDaiichi Sankyo Co., Ltd.NCT02848170Written as CS-3150How we know
- Study of CS-3150 in Combination With ARB or ACE Inhibitor in Hypertensive Patients With Moderate Renal ImpairmentCompletedPhase 3Daiichi Sankyo Co., Ltd.NCT02807987Written as CS-3150How we know
Codes
What other systems call esaxerenone · ClinicalTrials.gg INT000456
- MeSH (NLM) C000607547esaxerenoneOne source NLM
- UNII (FDA) N62TGJ04A1ESAXERENONEConfirmed FDA, NLM, Wikidata
- Wikidata Q27284603esaxerenoneConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C174741EsaxerenoneOne source FDA
- DrugBank DB15207One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000607547 | esaxerenone | One source NLM |
| UNII (FDA) | N62TGJ04A1 | ESAXERENONE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27284603 | esaxerenone | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C174741 | Esaxerenone | One source FDA |
| DrugBank | DB15207 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.